In the 2026 China PIII, Hansoh Pharma ranked 3rd in Innovation and 6th in Invention. In 2025, Hansoh's innovation transformation continued to bear fruit: the rising share of innovative drug revenue, the accelerating maturation of its late-stage pipeline, and breakthroughs in overseas licensing and registration of its proprietary innovative assets together underpinned its entry into the top three of the Innovation ranking. With the commercial foundation of its core products continuing to strengthen and R&D expertise in key therapeutic areas deepening, the company is progressively establishing a development path centered on proprietary innovation and supported by commercial translation and global collaboration.

Sustained growth in innovative drug revenue and steady pipeline progress form the main pillars of Hansoh's innovation transformation. In 2025, the company recorded revenue of approximately RMB 15.028 billion, up approximately 22.6% YoY, of which sales of innovative drugs and partnered products amounted to approximately RMB 12.354 billion, or 82.2% of total revenue, further consolidating the dominant position of innovative products in its revenue mix. Meanwhile, full-year R&D expenditure was approximately RMB 3.358 billion, up approximately 24.3% YoY; sustained R&D investment has been accompanied by pipeline expansion and progress in late-stage programs. As of the end of 2025, the company was conducting more than 70 clinical trials of innovative drugs, with eight new drug candidates entering clinical development during the year. As a result, its pipeline maintains a sufficient reserve of programs to drive future growth...

Download the report to see the full company profile.